Chardan Capital Has Bullish Outlook for ABUS FY2025 Earnings

Arbutus Biopharma Co. (NASDAQ:ABUS) – Equities researchers at Chardan Capital lifted their FY2025 earnings per share estimates for shares of Arbutus Biopharma in a report released on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will post earnings of ($0.30) per share for the year, up from their previous forecast of ($0.38). The consensus estimate for Arbutus Biopharma’s current full-year earnings is ($0.39) per share.

Several other analysts also recently commented on ABUS. StockNews.com downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat.com, Arbutus Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $5.50.

Arbutus Biopharma Stock Down 2.4 %

Shares of ABUS opened at $3.27 on Thursday. Arbutus Biopharma has a twelve month low of $2.30 and a twelve month high of $4.73. The company has a market capitalization of $619.64 million, a P/E ratio of -7.60 and a beta of 1.93. The firm has a 50 day moving average of $3.33 and a 200 day moving average of $3.58.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The business had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%.

Institutional Investors Weigh In On Arbutus Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its holdings in shares of Arbutus Biopharma by 3.3% during the 4th quarter. Wellington Management Group LLP now owns 513,302 shares of the biopharmaceutical company’s stock valued at $1,678,000 after buying an additional 16,484 shares during the period. Two Seas Capital LP increased its position in Arbutus Biopharma by 4.2% during the fourth quarter. Two Seas Capital LP now owns 8,740,956 shares of the biopharmaceutical company’s stock valued at $28,583,000 after acquiring an additional 353,568 shares during the last quarter. Whitefort Capital Management LP lifted its holdings in Arbutus Biopharma by 2.9% in the fourth quarter. Whitefort Capital Management LP now owns 13,241,916 shares of the biopharmaceutical company’s stock valued at $43,301,000 after acquiring an additional 373,949 shares during the period. Woodline Partners LP boosted its position in Arbutus Biopharma by 45.4% in the fourth quarter. Woodline Partners LP now owns 971,628 shares of the biopharmaceutical company’s stock worth $3,177,000 after purchasing an additional 303,475 shares during the last quarter. Finally, Saba Capital Management L.P. grew its stake in shares of Arbutus Biopharma by 31.3% during the 4th quarter. Saba Capital Management L.P. now owns 887,993 shares of the biopharmaceutical company’s stock valued at $2,904,000 after purchasing an additional 211,566 shares during the period. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.